with more than 70% of patients having dysgranulopoiesis and dysmegakaryopoiesis. This frequency is clearly higher than the frequency of AML trilineage among AML de novo. Trilineage dysplasia does not influence the rate of remission after chemotherapy. On the other hand, this trilineage dysplasia is correlated with cytogenetic abnormalities favoring the expansion of dysplastic clones.
We confirm that karyotype is a potent prognostic factor in high-grade MDS and AML6 (median survival of 6 months for the high-risk group vs 14 months for the intermediate risk group). In our AML6 study, we found chromosomic abnormalities such as alterations of chromosomes 5 and 7 in six out of 17 karyotypes (35%). In secondary AML, the incidence of these karyotype abnormalities was 10-15%. In myelodysplastic syndromes, the deletion of the long arm of the chromosome 5 is more frequent (40-60%). In the literature, losses of material on the chromosome 7 have an incidence of 30% in RAEB and RAEB-t. In our study, chromosome 7 mutations were found in 26% of AML6 and 24% of RAEB-t. Patients (67%) having chromosomes 5 and 7 abnormalities had received chemotherapy for a haematologic or solid neoplasia, or an exposure to professional mutagenic agents in our study.
The long-term survivors of our study received allogeneic bone marrow tranplantation. Bone marrow transplantation could improve event-free survival of AML6. A therapeutic decisional tree according to the age, the degree of dysplasia, the cytogenetics and not the number of erythroblasts and blasts myeloids would be more adequate. As of the high median age, the nonmyeloablative allogeneic stem cell transplantation should be evaluated in this pathology. Initial response to glucocorticoid (GC) treatment is an important prognostic factor in childhood acute lymphoblastic leukemia (ALL). 1 However, the molecular basis underlying GC action in ALL is controversial. The intracellular effects of GC are mediated by human glucocorticoid receptors (hGR), which once activated by ligand binding migrate to the nucleus, where they may act as positive or negative transcription regulators. Activated hGR mono/homodimers recognize and interact with glucocorticoidresponsive elements (GRE) located in the promoter region of different genes. Moreover, hGR may also interact with important transcriptional factors such as activator protein-1 (AP-1) and nuclear factor kB (NFkB), 2 which are transrepressed. Different hGR isoforms have been identified: hGRa, hGRb, hGRg, hGR-A and hGR-P, of which hGRa is thought to be the primary mediator of glucocorticoid action, whereas in the other isoforms Survival according to karyotype risk.
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the ligand-binding (hGRb, hGR-P) or the DNA-binding domain (hGR-A, hGRg) is disrupted. hGRb is generated by the alternative splicing of the ninth exon at the 3 0 end of the GR gene, and the resulting protein differs by only the 15 carboxyterminal amino acids. As hGRb lacks the ligand-binding domain, it is unable to modulate the expression of GCresponsive genes, and is thought to be a dominant-negative modulator of the hGRa isoform. In fact, hGRb was able to disrupt the hGRa-dependent activation of a MMTV-luciferase construct in COS-7 cells. 3 Reduced hGRa/hGRb ratio, due to decreased a and increased b isoforms expression, was reported in a GC-resistant chronic lymphocytic leukemia (CLL) case. 4 In ALL, the T-lineage blasts are more resistant to GC and express lower hGRa/hGRb ratio than the B-lineage ones, mainly due to the lower expression of hGRa. Compared to normal lymphocytes, pre-B ALL cells presented similar hGRa/hGRb ratios, despite the significant lower expression of hGRa. 5 However, the only study quantifying hGRa and hGRb protein levels compared leukemic lymphoid cells to EBV-transformed lymphocytes. Moreover, only eight pre-B ALL cases were analyzed. 5 We therefore compared the hGRb, hGRa and hGR protein levels in B-progenitors from ALL of the common subtype (cALL) with their normal bone marrow (BM) CD10 þ counterparts. In addition, the in vitro sensitivity to methylprednisolone-induced apoptosis was determined.
BM cells were obtained from 25 cALL patients at diagnosis and from 17 normal donors for BM transplantation. The study was carried out in accordance with the requirements of the local ethical committee. Mononuclear cells were isolated by density centrifugation with Histopaque 1077 (Sigma Diagnostics, St Louis, MO, USA) and stored at À701C at a density of 10 7 cells/ ml in RPMI 1640 medium with 20% fetal calf serum (FCS) and 10% DMSO. The monoclonal antibody (MAb) against hGRb was generated from splenocytes from mice immunized with a synthetic polypeptide corresponding to the hGRb 15 COOHterminal amino acids (N15I), 6 which are absent in hGRa. The anti-hGR MAb recognizing the sequence spanning from hGR Thr176 to Pro289, common to all hGR isoforms, was purchased from BD Transduction Laboratories (Becton Dickinson, San Diego, CA, USA) and the rabbit polyclonal anti-hGRa antibody from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The cells were permeabilized with BD FACS Permeabilizing Solution 2 (Becton Dickinson, San Diego, CA, USA) and incubated with saturating concentrations (previously titrated) of anti-hGRb, anti-hGR or anti-hGRa for 30 min at room temperature. After washing, the samples were incubated with saturating concentrations of goat anti-mouse (for anti-hGRb and anti-hGR) or mouse anti-rabbit antibodies (for anti-hGRa) conjugated with fluorescein isothiocyanate (FITC) at same conditions. After washing, the cell suspensions were labeled with anti-CD10 and anti-CD45 MAbs pre-conjugated with phycoerythrin (PE) and perdin chlorophyll protein (PerCP), respectively. hGRb and hGR specific antigen binding capacities (SABC) were determined using the pre-calibrated microbeads coated with different well-defined quantities of mouse MAb molecules (Dako QIFKIT Dako A/S, Glostrup, DK), and expressed as sites per cell, calculated as previously described. 7 hGRa expression was analyzed semiquantitatively by the mean fluorescence intensity (MFI) in arbitrary units (au). The B-progenitors were gated based on side scatter (SSC), forward scatter (FSC), CD45 and CD10 labeling. Normal and leukemic BM cells were incubated with 100 mg/ml of methylprednisolone for 12 h and the percentage of apoptotic and necrotic cells was determined by flow cytometry using Annexin V-FITC and propidium iodide staining. 159.6752.7 au; P ¼ 0.03). However, the ratio between hGRb/ hGR SABCs was not significantly different (0.1670.06 vs 0.370.16 in cALL and normal BM cells, respectively; P ¼ 0.15; Figure 1b) , due to the balanced increase of all isoforms. It must be pointed out that the anti-hGRa and antihGRb Mabs used in the present study can also detect the hGRg isoform, which is a splice variant that differs from hGRa and hGRb by the insertion of an arginine within the DNA-binding domain of the hGR (amino-acid position 453). 8 Although this cross-reactivity with hGRg could have affected the semiquantitative analyses of the a and b isoforms, it does invalidate our results, since it influenced the values obtained for hGRa and hGRb in equal terms. Finally, Figure 1c shows that no correlation was found between the hGRb/hGR SABCs ratio and the in vitro induction of apoptosis by methylprednisolone either in normal or leukemic cells.
Our results contrast with those by Longui et al, 5 who reported lower levels of hGRa and similar amounts of hGRb in leukemic pre-B cells compared to normal controls. Nevertheless, the hGRa/hGRb ratio was also not significantly different. Longui et al used a quantitative Western method, in which the peptides were coupled to albumin and used to create standard curves. However, the efficiency of coupling per se was not subjected to control. Quantitative flow cytometry is a reproducible technique based on the linear relationship between fluorescence intensity and the number of molecules, as determined by radioisotopic methods. 9 Moreover, by employing a multiparametric analysis, cALL blast counterparts from the normal BM were gated, excluding other lineages and mature lymphocytes.
hGRb was reported to act in a dominant-negative manner on hGRa function. However, the relative amount of b isoform necessary to confer resistance to GC-induced apoptosis is higher than those observed in the present study in the cALL cells. The hGRb/hGR SABCs ratio ranged from 0.07 to 0.46 and did not correlate with the GC-induced apoptosis, either in normal or in cALL B-progenitors. In neutrophils, which are markedly less sensitive to GC than lymphocytes, the ratio of hGRb to hGRa was found to be more than 70-fold greater than in normal peripheral blood mononuclear cells. 10 It is interesting to point out that in COS-1 and A549 cells overexpressing hGRb, the latter did not prevent hGRa from transrepressing AP-1 and NFkB activity. In addition, both isoforms were able to repress these factors GC-independently. 2 Changes in hGR isoform expression during B-cell ontogenesis are unknown. We, therefore, also analyzed mature B cells from the peripheral blood of 11 patients with CLL, and detected higher hGRb SABC (58.9713.8 Â 10 3 sites/cell; P ¼ 0.01) and lower hGRa MFI values (92.5772.7 au; Po0.001) than those of cALL blasts, suggesting that hGR levels may vary with B-cell maturation and in different lymphoproliferative disorders. In fact, in a GC-resistant CLL patient reported by Shahidi et al, 4 the hGRa/hGRb ratio was more than 15-fold lower than that observed in normal controls, due to a marked reduction of a isoform and a slightly higher concentration of hGRb.
In conclusion, we demonstrated a higher expression of a and b isoforms of the hGR in leukemic B-progenitors compared to normal CD10 þ BM cells. Moreover, our results indicated that the relative amount of each isoform did not differ significantly between normal and leukemic cells, and that there is no correlation between hGRb/hGR ratios and susceptibility to methylprednisolone-induced apoptosis. Therefore, the relevance of the dominant-negative action of hGRb to leukemogenesis and GC-resistance in B-lineage ALL seems unlikely.
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